Organization
Bexon Clinical Consulting LLC
2 abstracts
Abstract
CLDN6 CAR-T cell therapy of relapsed/refractory solid tumors ± a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01 phase 1 trial using an automated product.Org: Friedrich-Alexander University Erlangen-Nuremberg, Netherlands Cancer Institute, Hannover Medical School, University Hospital Hamburg Eppendorf, University Medical Center Mainz,
Abstract
Preliminary pharmacokinetic and safety data after a single intravenous infusion of Voyager-V1 (VV1, VSV-IFNβ-NIS) oncolytic virus in patients with relapsed refractory hematologic malignancies.Org: Vyriad, Mayo Clinic, Mayo Clinic, Division of Hematology, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Alliance Statistics and Data Management Center,